This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Vanity Fare

Click here for an archive of Cramer's "Mad Money" recaps.


The Fountain of Acquisition

Merger stories come and go and rarely make you money, but Jim Cramer on Wednesday's "Mad Money" TV show told viewers to start buying Allergan (AGN - Get Report) because it acquired Inamed (IMDC).

The stock is down because of the acquisition, a purchase that will ultimately make it a one-stop shop for artificial youth.

"And there's a bull market in artificial youth," Cramer said, adding that the aging boomers are one of the vainest generations in history.

With the acquisition, Allergen will add more vanity procedures to its Botox treatment, the most popular nonsurgical procedure of 2004.

As for the competition, Cramer said that it's more exciting than Syneron Medical (ELOS - Get Report) and IntraLase (ILSE) because the deal allows it exposure to all cosmetic treatments.

Inamed brings to the table breast implants, skin graft alternatives to deal with scars and dermal-filler products to smooth wrinkles.

Calpine Can't Hurt You

Cramer also warned viewers that a Calpine bankruptcy doesn't mean trouble for its competitors, particularly Dynegy (DYN - Get Report).

It's not another cheap, debt-ridden utility company like Calpine, Cramer said.

Dynegy just got upgraded by Moody's, has a third of the debt that Calpine had and has seen three straight profitable quarters, he said.

"It should soon be universally considered if not good, viable -- and worth more than it's priced at," said Cramer.

A last key difference is that, unlike Calpine, Dynegy isn't dependent on natural gas. The company is using coal from the Powder River Basin, the largest source of coal in the U.S.

And with natural gas prices so high, coal starts to look a whole lot cheaper.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DYN $30.07 2.28%
IMDC $0.09 28.61%
AGN $307.51 0.20%
ELOS $10.57 -1.77%
AAPL $126.44 -0.13%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs